AI assistant
Neuland Laboratories Limited. — Earnings Release 2021
Jan 27, 2021
62255_rns_2021-01-27_1f835dc2-7c3b-4309-8466-526b6fa550b3.pdf
Earnings Release
Open in viewerOpens in your device viewer
NFU LAND WHERE OPPORTUNITY BECOMES REALITY
Neuland Laboratories Limited Sanali Info Park, 'A Btock. Ground Floor, 8-2-120/1 1 3 Road No. 2, Banjara Hills Hyderabad - 500 034. Telangana, India.
January 27, 2021
To
BSE Limited Phiroze Jeejeebhoy Towers, 25th Floor, DalaI Street, Mumbai - 400 001
Tel: 040 6761 1600 / 6761 1 700 Email: [email protected] www.neulandlabs.com
To
The National Stock Exchange of India Ltd Exchange Plaza, Bandra Kurla Complex, Bandra (E) Mumbai – 400 001
Scrip Code: 524558
Scrip Code: NEULANDLAB; Series: EQ
Dear Sirs,
Results Release and Earnings Call Notice
We refer to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), 2015 and enclose a copy of the Q3 FY 2020-2021 Earnings Call details, for your information and records
Thanking you,
Yours faithfully,
Company Secretary
Encl: As above
Rpajqtprpd (-)ffi t-e: San,III Info Park. IA1 Black Grc)IInd FIr)or R-2-1 )n/1 1 R Rnnd Nn ) Raniara Hill< HvdPrahad - SIInr)q4 Tolannan2 India I fINI Nln R c; I O c;TG 1 QR4PI fflflz12 Qq
==> picture [108 x 67] intentionally omitted <==
Neuland Laboratories Limited’s Q3FY21 Results Conference Call At 17:00 hrs. IST on February 2, 2021
Neuland Laboratories Limited will announce its results for the third quarter and nine months ended December 31, 2020 on February 2, 2021. The results will also be made available on the website of the Company, www.neulandlabs.com
Following the announcement, the management of the Company will host an Earnings Call on the
2 February at 17:00 hrs . The details of the earnings call are:
Date: February 2, 2021
Time: 17:00 Hrs
Dial-in Numbers:
+91 22 6280 1107 / +91 22 7115 8008
For Diamond Pass Please Click Here:
Diamond Pass
Local Access Number: +91 70456 71221 (Available all over India)
International Toll-Free Number: USA – 18667462133 | UK – 08081011573 | Singapore – 8001012045 | Hong Kong – 800964448
About Neuland Laboratories Limited (BSE:524558, NSE: NEULANDLAB)
For over 37 years, Neuland Labs has been at the forefront of manufacturing APIs through its cGMP manufacturing facilities, working with customers in close to 80 countries. Neuland Labs has developed more than 300 processes and 75 APIs and has filed over 898+ Regulatory filings in the US (57 active US DMFs), the European Union (EU) and other geographies. Its manufacturing facilities are inspected and approved by the U.S. FDA and other leading regulatory agencies. Its record of quality manufacturing and reliability is highlighted by cGMP certifications that include the U.S. FDA, TGA (Australia), EDQM (EU), German Health Authority, ANVISA (Brazil), EMA (EU), Cofepris (Mexico), KFDA (Korea), PMDA (Japan), CFDA (China), FSI “SID &GP” Russia, Health Canada, ISO 9001, ISO14001, OHSAS18001 and ISO 27001.
For more information, visit www.NeulandLabs.com.
For more queries please contact:
Neuland: [email protected] OR Diwakar Pingle: [email protected]